Triodos Investment Management BV Acquires 1,500 Shares of Edwards Lifesciences Corporation $EW

Triodos Investment Management BV increased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 0.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 509,258 shares of the medical research company’s stock after acquiring an additional 1,500 shares during the quarter. Edwards Lifesciences comprises about 3.0% of Triodos Investment Management BV’s investment portfolio, making the stock its 11th largest holding. Triodos Investment Management BV’s holdings in Edwards Lifesciences were worth $39,829,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Allspring Global Investments Holdings LLC grew its stake in Edwards Lifesciences by 0.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock worth $2,170,000 after buying an additional 145 shares in the last quarter. Pacific Capital Partners Ltd acquired a new stake in Edwards Lifesciences during the second quarter worth about $1,760,000. Czech National Bank grew its stake in Edwards Lifesciences by 5.8% during the second quarter. Czech National Bank now owns 143,385 shares of the medical research company’s stock worth $11,214,000 after buying an additional 7,917 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in Edwards Lifesciences by 13.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company’s stock worth $5,582,000 after buying an additional 9,188 shares in the last quarter. Finally, Dynamic Advisor Solutions LLC grew its stake in Edwards Lifesciences by 2.4% during the first quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company’s stock worth $1,124,000 after buying an additional 370 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Stock Down 0.7%

NYSE:EW opened at $75.17 on Friday. The firm’s 50 day simple moving average is $78.20 and its 200 day simple moving average is $76.08. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. Edwards Lifesciences Corporation has a one year low of $64.89 and a one year high of $83.00. The company has a market cap of $44.13 billion, a PE ratio of 10.82, a P/E/G ratio of 3.64 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period last year, the company earned $0.70 EPS. The firm’s revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daniel J. Lippis sold 4,114 shares of the firm’s stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

EW has been the topic of a number of analyst reports. William Blair upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a research note on Friday, July 25th. Robert W. Baird increased their price objective on shares of Edwards Lifesciences from $78.00 to $79.00 and gave the stock a “neutral” rating in a research note on Friday, July 25th. Royal Bank Of Canada increased their price objective on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the stock an “outperform” rating in a research note on Friday, July 25th. The Goldman Sachs Group restated a “buy” rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. Finally, Wall Street Zen downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $87.06.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.